Q1 EPS Forecast for Prelude Therapeutics Raised by Analyst

Prelude Therapeutics Incorporated (NASDAQ:PRLD) – Analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of Prelude Therapeutics in a research note issued on Tuesday, April 8th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.47) per share for the quarter, up from their prior estimate of ($0.48). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Prelude Therapeutics’ current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Prelude Therapeutics’ Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($1.94) EPS.

Prelude Therapeutics (NASDAQ:PRLD) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.11. The company had revenue of $4.00 million for the quarter.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $4.00 price target (down from $7.00) on shares of Prelude Therapeutics in a research note on Wednesday, December 11th.

Prelude Therapeutics Price Performance

Shares of NASDAQ:PRLD opened at $0.66 on Thursday. The company has a market capitalization of $36.66 million, a price-to-earnings ratio of -0.37 and a beta of 1.35. The firm’s 50 day simple moving average is $0.80 and its 200 day simple moving average is $1.14. Prelude Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $6.80.

Insider Transactions at Prelude Therapeutics

In related news, insider Andrew Combs purchased 100,000 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was acquired at an average cost of $0.69 per share, with a total value of $69,000.00. Following the transaction, the insider now owns 480,123 shares of the company’s stock, valued at $331,284.87. This represents a 26.31 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Krishna Vaddi acquired 675,000 shares of Prelude Therapeutics stock in a transaction on Tuesday, March 25th. The stock was acquired at an average price of $0.69 per share, with a total value of $465,750.00. Following the purchase, the chief executive officer now directly owns 1,999,296 shares in the company, valued at approximately $1,379,514.24. This trade represents a 50.97 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 822,500 shares of company stock valued at $568,475 over the last ninety days. 62.80% of the stock is owned by company insiders.

Institutional Trading of Prelude Therapeutics

Large investors have recently modified their holdings of the business. XTX Topco Ltd bought a new stake in Prelude Therapeutics in the third quarter valued at approximately $100,000. State Street Corp lifted its position in Prelude Therapeutics by 35.1% in the third quarter. State Street Corp now owns 286,046 shares of the company’s stock valued at $592,000 after purchasing an additional 74,300 shares during the last quarter. Barclays PLC lifted its position in Prelude Therapeutics by 86.0% in the third quarter. Barclays PLC now owns 27,165 shares of the company’s stock valued at $57,000 after purchasing an additional 12,564 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Prelude Therapeutics by 8.2% during the third quarter. Geode Capital Management LLC now owns 391,716 shares of the company’s stock valued at $811,000 after buying an additional 29,765 shares during the period. Finally, Walleye Capital LLC increased its stake in shares of Prelude Therapeutics by 446.2% during the third quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock valued at $172,000 after buying an additional 67,946 shares during the period. Institutional investors own 79.72% of the company’s stock.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.